Biological
BAX 855 clinical trials
Also written BAX 855, ADYNOVATE and PEGylated Recombinant Factor VIII.
- studies test it
- 9
- open now
- 0
- in phase 3
- 6
- first study started
- 2011
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 3
- 6
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 1
Baxalta now part of Shire (6) · Takeda (1) · Bayer (1) · University of Texas Southwestern Medical Center (1)
Often tested with
Tested in the same studies.
Antihemophilic factor, human recombinant (2) · F8 protein, human (2) · Damoctocog alfa pegol (1) · Factor VIII-Fc fusion protein (1) · Emicizumab (1)
Studies
Open first, then newest update. How each study uses BAX 855 is read from its arms, and is right about nine times in ten.
Testing it · 9
- POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement TherapiesWithdrawnPhase 4University of Texas Southwestern Medical CenterNCT04690322Written as Adynovate
- A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia ACompletedPhase 3Baxalta now part of ShireNCT02615691Written as PEGylated Recombinant Factor VIII
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedPhase 3TakedaNCT05707351Written as Adynovate
- BAX 855 PK-guided DosingCompletedPhase 3Baxalta now part of ShireNCT02585960Written as PEGylated Recombinant Factor VIII
- BAX 855 Pediatric StudyCompletedPhase 3Baxalta now part of ShireNCT02210091Written as PEGylated Recombinant Factor VIII
- BAX 855 ContinuationCompletedPhase 3Baxalta now part of ShireNCT01945593Written as BAX855
- Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical ProceduresCompletedPhase 3Baxalta now part of ShireNCT01913405Written as PEGylated Recombinant factor VIII (rFVIII)
- BAX 855 Dose-Escalation Safety StudyCompletedPhase 1Baxalta now part of ShireNCT01599819Written as PEGylated Recombinant Factor VIII
- Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)CompletedPhase 1BayerNCT04015492Written as Rurioctocog alfa pegol (Adynovi)
Given in every arm · 2 — BAX 855 is usual care beside what is tested
- Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia ACompletedPhase 1SanofiNCT05042440Written as Rurioctocog alfa pegol
- Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)CompletedPhase 2/3Baxalta now part of ShireNCT01736475Written as PEGylated Recombinant Factor VIII
Codes
What other systems call BAX 855 · ClinicalTrials.gg INT000517
- MeSH (NLM) C000609799BAX 855Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5X3GF74R79RURIOCTOCOG ALFA PEGOLConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000609799 | BAX 855 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5X3GF74R79 | RURIOCTOCOG ALFA PEGOL | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.